Cyclerion Stock Story

CYCN -  USA Stock  

USD 1.90  0.28  12.84%

Cyclerion Therapeutics Net Cash Flow from Investing is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Investing is estimated at 19,421.05. Share Based Compensation is expected to rise to about 15.3 M this year, although the value of Average Assets will most likely fall to about 111.2 M. In this post, we will outline Cyclerion Therapeutics. We will evaluate if Cyclerion Therapeutics shares are reasonably priced going into December. In this post, I will also go over some essential variables affecting Cyclerion Therapeutics' products, and show how it may impact Cyclerion Therapeutics outlook for active traders this year.
Published few days ago
View all stories for Cyclerion Therapeutics | View All Stories
Is Cyclerion Therapeutics about to turn this around?
The firm shows a Beta (market volatility) of 1.0014, which signifies a somewhat significant risk relative to the market. Let's try to break down what Cyclerion's beta means in this case. Cyclerion Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Cyclerion Therapeutics is expected to follow. Even though it is essential to pay attention to Cyclerion Therapeutics historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy in foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Cyclerion Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate its performance. Cyclerion Therapeutics has an expected return of -0.24%. Please be advised to confirm Cyclerion Therapeutics standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Cyclerion Therapeutics performance from the past will be repeated at some point in the near future.

How important is Cyclerion Therapeutics's Liquidity

Cyclerion Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Cyclerion Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cyclerion Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cyclerion Therapeutics's total debt and its cash.

How Cyclerion utilizes its cash?

To perform a cash flow analysis of Cyclerion Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cyclerion Therapeutics is receiving and how much cash it distributes out in a given period. The Cyclerion Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Cyclerion Therapeutics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (78.21 Million)

Acquisition by Lovell Stephanie of 10000 shares of Cyclerion Therapeutics subject to Rule 16b-3

Legal trades by Cyclerion Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cyclerion insider trading alert for grant of stock option (right to buy) by Lovell Stephanie, the corporate stakeholder, on 28th of June 2021. This event was filed by Cyclerion Therapeutics In with SEC on 2021-06-28. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Cyclerion Therapeutics valued adequately by the market?

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cyclerion Therapeutics has an asset utilization ratio of 1.79 percent. This suggests that the company is making $0.0179 for each dollar of assets. An increasing asset utilization means that Cyclerion Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.

Will Cyclerion Therapeutics latest rise continue?

The maximum drawdown is down to 19.99 as of today. Cyclerion Therapeutics exhibits very low volatility with skewness of 1.82 and kurtosis of 6.63. However, we advise investors to further study Cyclerion Therapeutics technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cyclerion Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cyclerion Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Cyclerion Therapeutics Implied Volatility

Cyclerion Therapeutics' implied volatility exposes the market's sentiment of Cyclerion Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cyclerion Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cyclerion Therapeutics stock will not fluctuate a lot when Cyclerion Therapeutics' options are near their expiration.

Our Takeaway on Cyclerion Therapeutics Investment

Whereas some other entities under the biotechnology industry are still a bit expensive, Cyclerion Therapeutics may offer a potential longer-term growth to institutional investors. While some institutional investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Cyclerion Therapeutics.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Cyclerion Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com